EGFR Overexpression and Sequence Analysis of KRAS, BRAF, and EGFR Mutation Hot Spots in Canine Intestinal Adenocarcinoma. Issue 4 (July 2021)

• Record Type: Journal Article
• Authors: Cho, Seung-Hee; Seung, Byung-Joon; Kim, Soo-Hyeon; Bae, Min-Kyung; Lim, Ha-Young; Sur, Jung-Hyang
• Is Part Of: Veterinary pathology. Volume 58:Issue 4(2021)
• Page Start: 674
• Page End: 682
• Publication Date: 2021-07
• Subjects: BRAF -- canine intestinal adenocarcinoma -- EGFR -- KRAS -- mutation; Veterinary pathology -- Periodicals; Pathology, Veterinary -- Periodicals; 636.089607
• DOI: 10.1177/03009858211009778
• Languages: English
• ISSNs: 0300-9858

Abstract

Epidermal growth factor receptor (EGFR) is overexpressed in many human colorectal cancers and anti-EGFR agents are employed as immunotherapies. However, KRAS, EGFR, and BRAF gene mutations can influence the activity of the anti-EGFR agents. We evaluated EGFR expression at protein and mRNA levels in canine intestinal adenocarcinomas using immunohistochemistry (IHC) and RNA in situ hybridization (RNA-ISH). We also investigated the mutation status of EGFR, KRAS, and BRAF to aid the development of anti-EGFR agents for canine intestinal adenocarcinoma. EGFR expression was highest in adenocarcinoma, followed by intramucosal neoplasia (adenoma and in situ carcinoma), and nonneoplastic canine intestinal tissue, at both protein ( P = .000) and mRNA ( P = .005) levels. The EGFR, KRAS, and BRAF genes showed wild-type sequences at the mutation hot spots in all 13 specimens. Thus, EGFR might serve as a promising diagnostic marker in canine intestinal adenocarcinoma, and further studies would be needed to develop EGFR-targeted anticancer therapies.